Theralase Technologies Inc. (CVE:TLT – Get Free Report)’s stock price shot up 2.1% during trading on Tuesday . The company traded as high as C$0.25 and last traded at C$0.24. 47,802 shares were traded during mid-day trading, a decline of 83% from the average session volume of 273,888 shares. The stock had previously closed at C$0.24.
Theralase Technologies Stock Up 2.1%
The company has a market cap of C$70.96 million, a P/E ratio of -17.14 and a beta of -0.41. The company has a quick ratio of 3.40, a current ratio of 1.37 and a debt-to-equity ratio of 22.13. The business’s 50 day moving average is C$0.27 and its 200 day moving average is C$0.25.
About Theralase Technologies
Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.
Recommended Stories
- Five stocks we like better than Theralase Technologies
- 5 High-Yield Stocks With Analyst Support and Room to Run
- AST SpaceMobile Announces Launch Date for Its Next 3 BlueBird Satellites
- Is Lennar Finally Turning the Corner After Its Housing Slump?
- AI Memory Demand Has Turned These 5 S&P 500 Stocks Into Market Leaders
Receive News & Ratings for Theralase Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theralase Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
